Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Improving TB vaccine trial efficiency: A tough nut to crack.

Mcshane H., (2023), The Journal of infectious diseases

Controlled human infection models in COVID-19 and tuberculosis: current progress and future challenges.

Morrison H. et al, (2023), Frontiers in immunology, 14

Practical considerations for a TB controlled human infection model (TB-CHIM); the case for TB-CHIM in Africa, a systematic review of the literature and report of 2 workshop discussions in UK and Malawi.

Gordon SB. et al, (2023), Wellcome Open Res, 8

Inflammation and immune activation are associated with risk of Mycobacterium tuberculosis infection in BCG-vaccinated infants

Satti I. et al, (2022), Nature Communications, 13

Ethics review of COVID-19 human challenge studies: A joint HRA/WHO workshop.

Williams E. et al, (2022), Vaccine, 40, 3484 - 3489

Functional in-vitro evaluation of the non-specific effects of BCG vaccination in a randomised controlled clinical study.

Wilkie M. et al, (2022), Scientific reports, 12

Tuberculosis vaccines in the era of Covid-19 - what is taking us so long?

Dockrell HM. and McShane H., (2022), EBioMedicine, 79

Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults.

Killingley B. et al, (2022), Nat Med

Challenges in Developing a Controlled Human Tuberculosis Challenge Model.

Jackson S. and McShane H., (2022), Curr Top Microbiol Immunol

Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial

Fisher BA. et al, (2022), The Lancet Respiratory Medicine, 10, 255 - 266

Rapid research response to the COVID-19 pandemic: perspectives from a National Institute for Health Biomedical Research Centre.

Henderson LR. et al, (2022), Health research policy and systems, 20

“It seems impossible that it’s been made so quickly”: a qualitative investigation of concerns about the speed of COVID-19 vaccine development and how these may be overcome

Brown P. et al, (2022), Human Vaccines & Immunotherapeutics, 1 - 8

A large National Institute for Health Research (NIHR) Biomedical Research Centre facilitates impactful cross-disciplinary and collaborative translational research publications and research collaboration networks: a bibliometric evaluation study

Kiparoglou V. et al, (2021), Journal of Translational Medicine, 19

Distinct blood transcriptomic signature of treatment in latent tuberculosis infected individuals at risk of developing active disease.

Burel JG. et al, (2021), Tuberculosis (Edinburgh, Scotland), 131

Lessons from the pandemic on the value of research infrastructure

Roope LSJ. et al, (2021), Health Research Policy and Systems, 19

SARS-CoV-2 Human Challenge Studies. Reply.

Rapeport G. et al, (2021), The New England journal of medicine, 385

SARS-CoV-2 Human Challenge Studies - Establishing the Model during an Evolving Pandemic.

Rapeport G. et al, (2021), The New England journal of medicine, 385, 961 - 964

Injection fears and COVID-19 vaccine hesitancy

Freeman D. et al, (2021), Psychological Medicine, 1 - 11

High-dose Mycobacterium tuberculosis aerosol challenge cannot overcome BCG-induced protection in Chinese origin cynomolgus macaques; implications of natural resistance for vaccine evaluation.

Sibley L. et al, (2021), Scientific reports, 11

Equity for excellence in academic institutions: a manifesto for change

Wedekind L. et al, (2021), Wellcome Open Research, 6, 142 - 142

Load More

1
2
3
4
5
6
7
...
»

Include forthcoming?